To mitigate potential risks, several safety measures have been proposed:
Using biocompatible and biodegradable materials for the shell to reduce biocompatibility issues. Controlling the size and concentration of microbubbles to minimize the risk of embolism. Monitoring patients closely during and after administration to identify any adverse reactions early. Conducting thorough preclinical studies to assess long-term safety.
